Search Results

You are looking at 61 - 70 of 746 items for :

  • "risk factors" x
  • Refine by Access: All x
Clear All
Full access

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Courtney Smith

DNMT3A, U2AF1, SRSF2, CBL, PRPF8, SETBP1 , and KRAS . 23 , 26 , 29 – 32 Mutations of SF3B1 have been associated with a more favorable prognosis, but this may not be an independent risk factor. 26 , 33 Mutations of TP53 are strongly associated

Full access

Shaneli A. Fernando and Stephen B. Edge

with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials . J Clin Oncol 2004 ; 22 : 4247 – 4254 . 7. Wallgren A Bonetti M Gelber RD . Risk factors

Full access

Myron Goldsmith, George Whitelaw, and Denise A. Cannaday

. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients . Cancer 2007 ; 110 : 2339 – 2346 . 11. Wagman LD Baird MF Bennett CL . NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic

Full access

Breast cancer risk factor analysis allows the identification of women at very high risk for the future development of breast cancer. However, estimating risk for the individual woman is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. These practice guidelines discuss known risk factors, strategies for reducing risk, and possible future developments.

For the most recent version of the guidelines, please visit

Full access

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole

/print certificate. Release date: May 13, 2013; Expiration date: May 13, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Identify the risk factors associated with penile cancer. Discuss the rationale for

Full access

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

treatment remains high. We performed a retrospective cohort analysis using population-based data to evaluate new and persistent opioid and benzodiazepine use and risk factors among patients with breast cancer who received curative-intent treatment. Methods

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

patients with non–small cell lung cancer treated using atezolizumab monotherapy, we analyzed the incidence, severity, time course, treatment, outcomes, and risk factors of various organ-specific irAEs and their relationships with response rates

Full access

Nisar Ahmad, Denise M. Adams, Jiang Wang, Rajan Prakash, and Nagla Abdel Karim

,000. 3 It is slightly more common in women, with a female-to-male ratio of approximately 1.6:1.0. Risk factors for HEHE are not well-known. An association of HEHE with oral contraceptives has been suggested but not completely established. 4 , 5 HEHE

Full access

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

intervene in a prospective fashion. In this study, we sought to measure the impact of nonadherence to NCCN Guidelines on survival and disease recurrence in patients with HNSCC at a large urban health center, and investigated risk factors predictive of delay

Full access

Taymeyah Al-Toubah, Eleonora Pelle, Tiffany Valone, Mintallah Haider, and Jonathan R. Strosberg

Pneumocystis pneumonia (PCP) and other opportunistic infections similar to that seen in the brain tumor population? 10 What are the rates of grade 4 cytopenias? Are there clinical risk factors for severe myelotoxicity? Can patients be safely treated for >1